<DOC>
	<DOCNO>NCT01683695</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , parallel , placebo-controlled , multiple dose study enroll approximately 40 systemic lupus erythematosus subject active lupus arthritis .</brief_summary>
	<brief_title>Safety Study AMG 557 Subjects With Lupus Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Diagnosis SLE least 6 month define recent American College Rheumatology criterion Presence lupus relate inflammatory arthritis least four tender four swollen joint ; Systemic Lupus Erythematosus Disease Activity Index ( SLEDAI ) â‰¥ 6 screening ; Other inclusion criterion may apply . Presence history vasculitis , presence history active lupus nephritis require therapy within last 3 year Any disorder ( include psychiatric ) , condition , clinically significant disease , disease activity relate SLE Positive HIV antibody , hepatitis B surface antigen antiHBc , hepatitis C antibodies Known residential exposure individual tuberculosis positive Quantiferon test PPD test screen Men woman reproductive potential , unwilling practice highly effective method birth control duration study Other exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Lupus Arthritis , Systemic Lupus Erythematosus , AMG 557 , Lupus</keyword>
</DOC>